Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

jrh34 May. 3 at 1:46 AM

$CRDF What will everyone say when Monday comes and goes and there is no news, no $PFE buyout, no new data, nothing. Just another down day? What will you say?

1 · Reply

josegodoy May. 2 at 9:05 PM

$PFE I’m looking at a $26 (stop (near term)) to $32+ PT

1 · Reply

NomadiCapital May. 2 at 5:31 PM

$PFE WHEELING PFE here is easy money. It eventually goes. 1) PFE still has monthly RSI divergence like $TGT did when I bought that. It’s PFE’s only time it’s had Monthly Divergence ever… 2) PFE oversold first time on 3Day and 4Day since April 2025. 3) PFE typical Uptrends & Downtrends ride the Green EMA. Currently about on it now 4) Generally paying highest dividend yield it’s ever had (just like TGT did) My bias is UP… but prepared for a “W” bottom. Will sell more puts in that case.

0 · Reply

Makingmillions192 May. 2 at 3:08 PM

$LEXX If Lexaria secures another MTA partner, things will get interesting fast. The real tide-turner, however, would be an 'Option-to-License' agreement. This would provide an upfront cash payment to maintain exclusivity while the final 2026 studies conclude. Frankly, given the extensive groundwork laid for the existing partner, this should be a straightforward win…. It is surprising they haven't yet secured a million-dollar payment with a milestone-based option; that move would send the stock skyrocketing and allow warrants to move into the money. Rich, it's time to roll up the sleeves... $LLY $VKTX $PFE $NVO

0 · Reply

CharlieeMungerTWITS May. 2 at 2:51 PM

$ARVN $PFE sounds sexy ! $IBB

0 · Reply

LongLTC May. 2 at 12:54 PM

$PFE

0 · Reply

TheWinningStock May. 2 at 12:40 PM

$CRDL <<---another winner 🤑 https://www.cardiolrx.com/cardiol-therapeutics-to-highlight-maveric-phase-iii-trial-and-recently-published-archer-results-in-live-interview-with-barchart/ $IBRX $PFE ....🤑🚀

0 · Reply

jrh34 May. 2 at 12:14 PM

$CRDF There is no powder keg, $PFE isn't buying them Monday, the technicals are lousy. My short position continues to print $.

1 · Reply

TheUnmaker May. 2 at 7:23 AM

$TNXP There is a reason we are an uplisted company. Don't be late to the party. Big things to come! $PFE $LLY $PG $JNJ https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-uplisting-from-nasdaq-capital-market-ok3to5zr8mfo.html

1 · Reply

TheUnmaker May. 2 at 7:19 AM

$TNXP This is the news we need to get our Lymes Diaease vaccine off the ground. This administration is causing a big shift in all industries as long as its meeting their standard. Don't be a skeptic, the Kennedys want this approved. Once we get further down the pipeline with FDA approval, than U believe the campaign to promote this will begin. Lymes Diaease effects alot of people and is a growing issue in the Northeast and Northern states of America. Big things coming. Continue to hold the lines bulls! $PFE $LLY $JNJ $PG https://www.hhs.gov/press-room/secretary-kennedy-convenes-lyme-disease-patients-providers-announce-new-diagnostic-efforts.htm

1 · Reply

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Apr 29, 2026, 7:42 AM EDT - 3 days ago

Pfizer's blood cancer drug meets main goal in late-stage trial

$Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma$

Apr 29, 2026, 6:45 AM EDT - 3 days ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 28, 2026, 1:23 PM EDT - 4 days ago

Pfizer Stock Is Declining Today: What's Happening?

Apr 28, 2026, 10:41 AM EDT - 4 days ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:17 AM EDT - 4 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 24, 2026, 8:36 AM EDT - 8 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Apr 23, 2026, 9:00 AM EDT - 9 days ago

Pfizer Transcript: AGM 2026

Apr 22, 2026, 4:45 PM EDT - 10 days ago

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 5:18 AM EDT - 10 days ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 21, 2026, 11:51 AM EDT - 11 days ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 20, 2026, 3:05 PM EDT - 12 days ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 6:45 AM EDT - 12 days ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 16, 2026, 1:01 PM EDT - 16 days ago

The Big 3: PFE, V, SYF

SYF V

Apr 10, 2026, 11:00 PM EDT - 22 days ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 9, 2026, 10:00 AM EDT - 23 days ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 7, 2026, 1:54 PM EDT - 25 days ago

Why Is Pfizer Stock Dropping Tuesday?

Apr 2, 2026, 11:14 AM EDT - 4 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Apr 1, 2026, 11:39 AM EDT - 4 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Apr 1, 2026, 10:13 AM EDT - 4 weeks ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Mar 30, 2026, 10:44 AM EDT - 4 weeks ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Mar 24, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 23, 2026, 12:46 PM EDT - 5 weeks ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Mar 23, 2026, 10:35 AM EDT - 5 weeks ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Mar 23, 2026, 9:36 AM EDT - 5 weeks ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Mar 23, 2026, 7:07 AM EDT - 5 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Mar 23, 2026, 7:02 AM EDT - 5 weeks ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Mar 23, 2026, 6:47 AM EDT - 5 weeks ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Mar 23, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

Mar 22, 2026, 9:45 AM EDT - 5 weeks ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Mar 20, 2026, 4:30 PM EDT - 6 weeks ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 19, 2026, 6:45 AM EDT - 6 weeks ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 18, 2026, 2:23 PM EDT - 6 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 17, 2026, 7:49 AM EDT - 6 weeks ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 6:45 AM EDT - 6 weeks ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 9, 2026, 7:27 AM EDT - 7 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 6, 2026, 12:40 AM EST - 2 months ago

China approves Pfizer GLP-1 drug for weight management

Mar 5, 2026, 4:48 PM EST - 2 months ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 4, 2026, 8:55 AM EST - 2 months ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Mar 3, 2026, 8:10 AM EST - 2 months ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Mar 2, 2026, 11:14 AM EST - 2 months ago

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 10:30 AM EST - 2 months ago

Pfizer Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 10:00 AM EST - 2 months ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 24, 2026, 2:29 PM EST - 2 months ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 7:45 AM EST - 2 months ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 23, 2026, 10:26 PM EST - 2 months ago

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 3:15 PM EST - 2 months ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Feb 23, 2026, 10:00 AM EST - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 18, 2026, 12:00 PM EST - 2 months ago

Is There 25% Downside For Pfizer Stock?

Feb 17, 2026, 6:45 AM EST - 2 months ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 13, 2026, 6:13 AM EST - 2 months ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

jrh34 May. 3 at 1:46 AM

$CRDF What will everyone say when Monday comes and goes and there is no news, no $PFE buyout, no new data, nothing. Just another down day? What will you say?

1 · Reply

josegodoy May. 2 at 9:05 PM

$PFE I’m looking at a $26 (stop (near term)) to $32+ PT

1 · Reply

NomadiCapital May. 2 at 5:31 PM

0 · Reply

Makingmillions192 May. 2 at 3:08 PM

0 · Reply

CharlieeMungerTWITS May. 2 at 2:51 PM

$ARVN $PFE sounds sexy ! $IBB

0 · Reply

LongLTC May. 2 at 12:54 PM

$PFE

0 · Reply

TheWinningStock May. 2 at 12:40 PM

0 · Reply

jrh34 May. 2 at 12:14 PM

$CRDF There is no powder keg, $PFE isn't buying them Monday, the technicals are lousy. My short position continues to print $.

1 · Reply

TheUnmaker May. 2 at 7:23 AM

1 · Reply

TheUnmaker May. 2 at 7:19 AM

1 · Reply

Biostock May. 2 at 2:12 AM

$SGMT has a first-line acne drug with a potential TAM exceeding $1 billion annually and holds global rights excluding China. Despite this, its market capitalization is only about half of the projected yearly sales. In contrast, $CELC has a second-line cancer drug partnered with $PFE , with a possible TAM under $2.5 billion, yet its market cap exceeds $6 billion. $QQQ $SPY

0 · Reply

DragonAlgo May. 2 at 2:07 AM

🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-05-08 | Strike: $26.50 | Type: PUT Option Plan (premium): Entry: $0.77 Stop: $0.55 TP1: $1.00 TP2: $1.31 TP3: $1.85 🔗 https://dragonalgo.com

0 · Reply

scotttrader213 May. 2 at 1:43 AM

$PFE one day, I hope to see a a drug company with an excellent pipeline, heading more into oncology, actually be in the 45-50 range, the dividend, does help..

0 · Reply

topstockalerts May. 1 at 11:35 PM

Arvinas shares surged after trading resumed on Friday following the U.S. FDA’s approval of VEPPANU (vepdegestrant), a drug developed in partnership with Pfizer, for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have already progressed after at least one line of endocrine therapy. The approval is a major milestone because VEPPANU becomes the first-ever PROTAC (proteolysis-targeting chimera) therapy authorized by the FDA. This class of drugs works by degrading disease-causing proteins rather than just blocking them, representing a new approach in targeted cancer treatment. According to Arvinas and Pfizer, the decision also came earlier than expected, being granted ahead of the formal PDUFA action date of June 5, 2026, signaling strong regulatory confidence in the treatment’s safety and efficacy profile. $ARVN $PFE

0 · Reply

amrsamir May. 1 at 10:41 PM

$PFE I found this article for you: - https://www.investing.com/news/stock-market-news/us-fda-approves-pfizer-arvinas-breast-cancer-drug-4654649

0 · Reply

TheUnmaker May. 1 at 10:32 PM

$TNXP $PFE $PG $JNJ $LLY

0 · Reply

TheUnmaker May. 1 at 10:14 PM

$TNXP "Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is 55.42 USD with a low forecast of 34.34 USD and a high forecast of 68.25 USD." https://www.alphaspread.com/security/nasdaq/tnxp/analyst-estimates $PFE $LLY $PG $JNJ

1 · Reply